Dongwha Pharm.Co.Ltd Total Liabilities
Dongwha Pharm.Co.Ltd total liabilities. Based on the latest financial reports, Dongwha Pharm.Co.Ltd (000020) has total liabilities worth ₩238.21 Billion KRW (≈ $161.43 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Dongwha Pharm.Co.Ltd (000020) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dongwha Pharm.Co.Ltd (2011–2025)
Total liabilities of Dongwha Pharm.Co.Ltd from 2011 to 2025. This chart illustrates how Dongwha Pharm.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Dongwha Pharm.Co.Ltd to see how much of total assets are deployed in long-term investments.
Dongwha Pharm.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Dongwha Pharm.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WW Holding Inc
TW:8442
|
Taiwan | NT$4.00 Billion |
|
K Laser Technology Inc
TW:2461
|
Taiwan | NT$4.41 Billion |
|
Nahar Spinning Mills Limited
NSE:NAHARSPING
|
India | Rs11.81 Billion |
|
Powercell Sweden
ST:PCELL
|
Sweden | Skr266.19 Million |
|
Orient Technologies Limited
NSE:ORIENTTECH
|
India | Rs2.33 Billion |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
Korea | ₩10.47 Billion |
|
Daechang Forgi
KO:015230
|
Korea | ₩81.19 Billion |
|
Vivani Medical Inc.
NASDAQ:VANI
|
USA | $22.67 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Dongwha Pharm.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dongwha Pharm.Co.Ltd balance sheet assets.
Liquidity & Leverage Metrics
Dongwha Pharm.Co.Ltd Total Liabilities Ratios Explained
Dongwha Pharm.Co.Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dongwha Pharm.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dongwha Pharm.Co.Ltd (2011–2025)
The table below shows the annual total liabilities of Dongwha Pharm.Co.Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩240.73 Billion ≈ $163.14 Million |
+10.45% |
| 2024-12-31 | ₩217.96 Billion ≈ $147.71 Million |
+38.02% |
| 2023-12-31 | ₩157.92 Billion ≈ $107.02 Million |
+91.50% |
| 2022-12-31 | ₩82.46 Billion ≈ $55.88 Million |
-5.94% |
| 2021-12-31 | ₩87.67 Billion ≈ $59.41 Million |
-3.79% |
| 2020-12-31 | ₩91.13 Billion ≈ $61.75 Million |
+21.25% |
| 2019-12-31 | ₩75.15 Billion ≈ $50.93 Million |
+2.67% |
| 2018-12-31 | ₩73.20 Billion ≈ $49.61 Million |
+4.15% |
| 2017-12-31 | ₩70.28 Billion ≈ $47.63 Million |
-1.95% |
| 2016-12-31 | ₩71.68 Billion ≈ $48.58 Million |
-17.68% |
| 2015-12-31 | ₩87.07 Billion ≈ $59.01 Million |
+4.47% |
| 2014-12-31 | ₩83.35 Billion ≈ $56.48 Million |
-6.28% |
| 2013-12-31 | ₩88.93 Billion ≈ $60.27 Million |
-8.59% |
| 2012-12-31 | ₩97.29 Billion ≈ $65.93 Million |
-11.40% |
| 2011-12-31 | ₩109.81 Billion ≈ $74.42 Million |
-- |
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more